PGR
Progesterone receptor
As of the edition of 20 October 2026, PGR (progesterone receptor, UniProt P06401) has 36 drugs tested at it and 47 companies on the list, 2 on route A and 16 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P06401
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 21
- Disease areas
- Urinary and reproductive; Pregnancy and women's health; Cancer; Hormones; Mental health; Skin and connective tissue; Nutrition and metabolism; Immune system
- Registered trials of its drugs
- 1,200
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 26 |
| Went quiet | 7 |
| Stopped | 3 |
| Total | 36 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Progesterone | Marketed | Phase 4 | none listed |
| Levonorgestrel | Marketed | Phase 4 | none listed |
| Mifepristone | Marketed | Phase 4 | none listed |
| Medroxyprogesterone acetate | Marketed | Phase 4 | none listed |
| Megestrol acetate | Marketed | Phase 4 | none listed |
| Drospirenone | Marketed | Phase 4 | none listed |
| Ulipristal acetate | Marketed | Phase 4 | none listed |
| Dydrogesterone | Marketed | Phase 4 | none listed |
| Etonogestrel | Marketed | Phase 4 | Ends 2029 |
| Norethindrone acetate | Marketed | Phase 4 | none listed |
| Dienogest | Marketed | Phase 4 | none listed |
| Norethindrone | Marketed | Phase 4 | none listed |
12 of 36 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 16 |
| Engaged | 18 |
| Undetermined | 11 |
| Total on the list | 47 |
| Company | Route |
|---|---|
| AbbVie | Route B |
| Eli Lilly | Route B |
| Linepharma | Route B |
The other 44 companies at PGR
In the product47 companies in all; 44 are not named here, and no score is.
See the 47 companies at PGR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.